Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

2014 ASH Annual Meeting

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survival and Subgroup Analysis From a Randomized Phase III Study of Intravenous Rigosertib vs Best Supportive Care in Patients With Higher-Risk Myelodysplastic Syndrome After Failure of Hypomethylating Agents,” presented by Guillermo Garcia-Manero, MD.

Time: 1:54

Richard M. Stone, MD, on the SWOG S1117 Study

Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “A Randomized Phase II Study of Azacitidine Combined With Lenalidomide or With Vorinostat vs Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117,” presented by Mikkael A. Sekeres, MD, MS.

Hematologic Malignancies

Keith McCrae, MD

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementation of a Heparin-Induced Thrombocytopenia Management Program Reduces the Cost of Diagnostic Testing and Pharmacologic Treatment in an Academic Medical Center,” presented by Caroline Dupre Vaughn, RN.

Leukemia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances in treating acute myeloid leukemia and the acute promyelocytic leukema subtype.

Lymphoma

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Bertrand Coiffier, MD, PhD, of the Centre Hospitalier Lyon-Sud discuss three French studies on rituximab maintenance vs wait and watch after R-DHAP in mantle cell lymphoma; R-CHOP with or without radiotherapy in diffuse large B-cell lymphoma; and romidepsin and CHOP in peripheral T-cell lymphoma.

Leukemia

Hagop Kantarjian, MD

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797, “First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Patients,” presented by Sabina Chiaretti, MD, PhD, and abstract 798, “Nilotinib and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1–Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02),” presented by Oliver G. Ottman, MD.

Dec

Today In Oncology

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Related Videos

Richard M. Stone, MD, on the SWOG S1117 Study

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers

Deb Schrag Elected 2027–2028 ASCO President

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns